<DOC>
	<DOCNO>NCT02064491</DOCNO>
	<brief_summary>The purpose study determine whether continue erlotinib beyond disease progression combination chemotherapy beneficial NSCLC patient EGFR mutant disease respond EGFR TKI .</brief_summary>
	<brief_title>Erlotinib Treatment Beyond Progression EGFR Mutant NSCLC</brief_title>
	<detailed_description>A Phase II randomise , multicenter study assess efficacy safety continue erlotinib addition chemotherapy versus chemotherapy alone patient EGFR mutant EGFR TKI responsive NSCLC progress EGFR TKI .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm stage IIIB/IV NSCLC . Investigator confirm progression accord RECIST 1.1 EGFR TKI treatment within 28 day randomization Activating mutation ( G719A/C/S ; Exon 19 insertion/deletion ; L858R ; L861Q ) EGFR gene least partial response EGFR TKI last ≥ 6 month Performance status : WHO 02 Measurable disease accord RECIST 1.1 Patients must able comply study treatment Women childbearing potential men reproductive potential must willing practice acceptable method birth control study Neutrophils ≥ 1'000/μl , Platelets ≥ 100'000/μl , Alanine amino transferase ≤ 2.5 × Upper limit normal ( ULN ) ( &lt; 5 × ULN liver metastasis ) , Alkaline phosphatase ≤ 2.5 × ULN ( &lt; 5 × ULN liver metastasis ) , Serum bilirubin ≤ 1.5 × ULN , Serum Creatinine ≤ 1.5 × ULN . Patient must able comply protocol RECIST 1.1 define disease progression 28 day previous EGFR TKI treatment . Patient treat investigational agent indication within 4 week study treatment . Patient history hypersensitivity intolerance erlotinib gefitinib . Patient history hypersensitivity intolerance chemotherapeutic agent use study . Patient symptomatic central nervous system metastases Patient know active hepatitis B C , HIV infection Pregnant breastfeeding . Patient uncontrolled undercurrent illness circumstance could limit compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>EGFR mutant</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Treatment Beyond Progression</keyword>
</DOC>